Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.
Journal
Journal of vascular and interventional radiology : JVIR
ISSN: 1535-7732
Titre abrégé: J Vasc Interv Radiol
Pays: United States
ID NLM: 9203369
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
22
11
2021
revised:
02
03
2022
accepted:
15
03
2022
pubmed:
30
3
2022
medline:
7
7
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
To characterize the effects of commonly used transcatheter arterial chemoembolization (TACE) regimens on the immune response and immune checkpoint marker expression using a VX2 rabbit liver tumor model. Twenty-four VX2 liver tumor-bearing New Zealand white rabbits were assigned to 7 groups (n = 3 per group) undergoing locoregional therapy as follows: (a) bicarbonate infusion without embolization, (b) conventional TACE (cTACE) using a water-in-oil emulsion containing doxorubicin mixed 1:2 with Lipiodol, drug-eluting embolic-TACE with either (c) idarubicin-eluting Oncozene microspheres (40 μm) or (d) doxorubicin-eluting Lumi beads (40-90 μm). For each therapy arm (b-d), a tandem set of 3 animals with additional bicarbonate infusion before TACE was added, to evaluate the effect of pH modification on the immune response. Three untreated rabbits served as controls. Tissue was harvested 24 hours after treatment, followed by digital immunohistochemistry quantification (counts/μm Lumi-bead TACE induced significantly more intratumoral T-cell and APC infiltration than cTACE and Oncozene-microsphere TACE. Additionally, tumors treated with Lumi-bead TACE expressed significantly higher intratumoral immune checkpoint markers compared with cTACE and Oncozene-microsphere TACE. Neoadjuvant bicarbonate demonstrated the most pronounced effect on cTACE and resulted in a significant increase in intratumoral cluster of differentiation 3 This preclinical study revealed significant differences in evoked tumor immunogenicity depending on the choice of chemoembolic regimen for TACE.
Identifiants
pubmed: 35346859
pii: S1051-0443(22)00155-5
doi: 10.1016/j.jvir.2022.03.026
pmc: PMC9344951
mid: NIHMS1825921
pii:
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Bicarbonates
0
Programmed Cell Death 1 Receptor
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
764-774.e4Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK034989
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206180
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB023366
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2022 SIR. Published by Elsevier Inc. All rights reserved.
Références
Oncogene. 2017 Oct 19;36(42):5829-5839
pubmed: 28604752
Cancer Res. 2013 Mar 1;73(5):1524-35
pubmed: 23288510
Hepatology. 2002 May;35(5):1164-71
pubmed: 11981766
Sci Rep. 2020 Nov 27;10(1):20785
pubmed: 33247185
J Vasc Interv Radiol. 2008 Dec;19(12):1740-8
pubmed: 18951042
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
Clin Cancer Res. 2006 Apr 15;12(8):2563-7
pubmed: 16638866
Clin Cancer Res. 2013 Dec 15;19(24):6678-85
pubmed: 24030702
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):335-42
pubmed: 16517780
Semin Cancer Biol. 2017 Apr;43:74-89
pubmed: 28267587
Eur Radiol. 2022 Apr;32(4):2437-2447
pubmed: 34718844
J Vasc Interv Radiol. 2020 Oct;31(10):1706-1716.e1
pubmed: 32684417
Radiology. 2013 Aug;268(2):470-80
pubmed: 23771914
J Hepatocell Carcinoma. 2020 Feb 10;7:11-17
pubmed: 32104669
Cancer Res. 2016 Mar 15;76(6):1381-90
pubmed: 26719539
Radiology. 2020 Sep;296(3):575-583
pubmed: 32633675
J Vasc Interv Radiol. 2008 Jun;19(6):931-6
pubmed: 18503910
J Vasc Interv Radiol. 2000 Nov-Dec;11(10):1245-55
pubmed: 11099235
Clin Cancer Res. 2020 Jan 15;26(2):428-438
pubmed: 31582517
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Cancer Res. 2012 Jun 1;72(11):2746-56
pubmed: 22593198
Radiology. 2019 Jul;292(1):25-34
pubmed: 31012818
J Comput Assist Tomogr. 2009 Jul-Aug;33(4):626-30
pubmed: 19638862
World J Hepatol. 2017 Jun 28;9(18):808-814
pubmed: 28706579
Anticancer Drugs. 2011 Sep;22(8):741-8
pubmed: 21487286